Efthymios D Avgerinos1, Wissam Jaber2, Joan Lacomis3, Kyle Markel4, Michael McDaniel2, Belinda N Rivera-Lebron5, Charles B Ross6, Jacob Sechrist3, Catalin Toma7, Rabih Chaer4. 1. Division of Vascular Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. Electronic address: avgerinose@upmc.edu. 2. Division of Cardiology, Department of Medicine, Emory University, Atlanta, Georgia, USA. 3. Department of Radiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. 4. Division of Vascular Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. 5. Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. 6. Division of Cardiology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. 7. Piedmont Heart Institute, Atlanta, Georgia, USA.
Abstract
OBJECTIVES: The aim of this trial was to determine whether ultrasound-assisted thrombolysis (USAT) is superior to standard catheter-directed thrombolysis (SCDT) in pulmonary arterial thrombus reduction for patients with submassive pulmonary embolism (sPE). BACKGROUND: Catheter-directed therapy has been increasingly used in sPE and massive pulmonary embolism as a decompensation prevention and potentially lifesaving procedure. It is unproved whether USAT is superior to SCDT using traditional multiple-side-hole catheters in the treatment of patients with pulmonary embolism. METHODS: Adults with sPE were enrolled. Participants were randomized 1:1 to USAT or SCDT. The primary outcome was 48-hour clearance of pulmonary thrombus assessed by pre- and postprocedural computed tomographic angiography using a refined Miller score. Secondary outcomes included improvement in right ventricular-to-left ventricular ratio, intensive care unit and hospital stay, bleeding, and adverse events up to 90 days. RESULTS: Eighty-one patients with acute sPE were randomized and were available for analysis. The mean total dose of alteplase for USAT was 19 ± 7 mg and for SCDT was 18 ± 7 mg (P = 0.53), infused over 14 ± 6 and 14 ± 5 hours, respectively (P = 0.99). In the USAT group, the mean raw pulmonary arterial thrombus score was reduced from 31 ± 4 at baseline to 22 ± 7 (P < 0.001). In the SCDT group, the score was reduced from 33 ± 4 to 23 ± 7 (P < 0.001). There was no significant difference in mean thrombus score reduction between the 2 groups (P = 0.76). The mean reduction in right ventricular/left ventricular ratio from baseline (1.54 ± 0.30 for USAT, 1.69 ± 0.44 for SCDT) to 48 hours was 0.37 ± 0.34 in the USAT group and 0.59 ± 0.42 in the SCDT group (P = 0.01). Major bleeding (1 stroke and 1 vaginal bleed requiring transfusion) occurred in 2 patients, both in the USAT group. CONCLUSIONS: In the SUNSET sPE (Standard vs. Ultrasound-Assisted Catheter Thrombolysis for Submassive Pulmonary Embolism) trial, patients undergoing USAT had similar pulmonary arterial thrombus reduction compared with those undergoing SCDT, using comparable mean lytic doses and durations of lysis.
OBJECTIVES: The aim of this trial was to determine whether ultrasound-assisted thrombolysis (USAT) is superior to standard catheter-directed thrombolysis (SCDT) in pulmonary arterial thrombus reduction for patients with submassive pulmonary embolism (sPE). BACKGROUND: Catheter-directed therapy has been increasingly used in sPE and massive pulmonary embolism as a decompensation prevention and potentially lifesaving procedure. It is unproved whether USAT is superior to SCDT using traditional multiple-side-hole catheters in the treatment of patients with pulmonary embolism. METHODS: Adults with sPE were enrolled. Participants were randomized 1:1 to USAT or SCDT. The primary outcome was 48-hour clearance of pulmonary thrombus assessed by pre- and postprocedural computed tomographic angiography using a refined Miller score. Secondary outcomes included improvement in right ventricular-to-left ventricular ratio, intensive care unit and hospital stay, bleeding, and adverse events up to 90 days. RESULTS: Eighty-one patients with acute sPE were randomized and were available for analysis. The mean total dose of alteplase for USAT was 19 ± 7 mg and for SCDT was 18 ± 7 mg (P = 0.53), infused over 14 ± 6 and 14 ± 5 hours, respectively (P = 0.99). In the USAT group, the mean raw pulmonary arterial thrombus score was reduced from 31 ± 4 at baseline to 22 ± 7 (P < 0.001). In the SCDT group, the score was reduced from 33 ± 4 to 23 ± 7 (P < 0.001). There was no significant difference in mean thrombus score reduction between the 2 groups (P = 0.76). The mean reduction in right ventricular/left ventricular ratio from baseline (1.54 ± 0.30 for USAT, 1.69 ± 0.44 for SCDT) to 48 hours was 0.37 ± 0.34 in the USAT group and 0.59 ± 0.42 in the SCDT group (P = 0.01). Major bleeding (1 stroke and 1 vaginal bleed requiring transfusion) occurred in 2 patients, both in the USAT group. CONCLUSIONS: In the SUNSET sPE (Standard vs. Ultrasound-Assisted Catheter Thrombolysis for Submassive Pulmonary Embolism) trial, patients undergoing USAT had similar pulmonary arterial thrombus reduction compared with those undergoing SCDT, using comparable mean lytic doses and durations of lysis.
Authors: Tyler L Bloomer; Georges E El-Hayek; Michael C McDaniel; Breck C Sandvall; Henry A Liberman; Chandan M Devireddy; Gautam Kumar; Pete P Fong; Wissam A Jaber Journal: Catheter Cardiovasc Interv Date: 2017-02-01 Impact factor: 2.692
Authors: Sorcha Allen; Lucas Chan; Dalila Masic; Katerina Porcaro; Stephen Morris; Jeremiah Haines; Ferdinand Leya; Carlos F Bechara; John Lopez; Bruce Lewis; Lowell Steen; Jawed Fareed; Amir Darki; Yevgeniy Brailovsky Journal: Thromb Res Date: 2021-03-16 Impact factor: 3.944
Authors: William T Kuo; Arjun Banerjee; Paul S Kim; Frank J DeMarco; Jason R Levy; Francis R Facchini; Kamil Unver; Matthew J Bertini; Akhilesh K Sista; Michael J Hall; Jarrett K Rosenberg; Miguel A De Gregorio Journal: Chest Date: 2015-09 Impact factor: 9.410
Authors: Efthymios D Avgerinos; Zein Saadeddin; Adham N Abou Ali; Larry Fish; Catalin Toma; Maria Chaer; Belinda N Rivera-Lebron; Rabih A Chaer Journal: J Vasc Surg Venous Lymphat Disord Date: 2018-07
Authors: Nils Kucher; Peter Boekstegers; Oliver J Müller; Christian Kupatt; Jan Beyer-Westendorf; Thomas Heitzer; Ulrich Tebbe; Jan Horstkotte; Ralf Müller; Erwin Blessing; Martin Greif; Philipp Lange; Ralf-Thorsten Hoffmann; Sebastian Werth; Achim Barmeyer; Dirk Härtel; Henriette Grünwald; Klaus Empen; Iris Baumgartner Journal: Circulation Date: 2013-11-13 Impact factor: 29.690
Authors: Belinda Rivera-Lebron; Michael McDaniel; Kamran Ahrar; Abdulah Alrifai; David M Dudzinski; Christina Fanola; Danielle Blais; David Janicke; Roman Melamed; Kerry Mohrien; Elizabeth Rozycki; Charles B Ross; Andrew J Klein; Parth Rali; Nicholas R Teman; Leoara Yarboro; Eugene Ichinose; Aditya M Sharma; Jason A Bartos; Mahir Elder; Brent Keeling; Harold Palevsky; Soophia Naydenov; Parijat Sen; Nancy Amoroso; Josanna M Rodriguez-Lopez; George A Davis; Rachel Rosovsky; Kenneth Rosenfield; Christopher Kabrhel; James Horowitz; Jay S Giri; Victor Tapson; Richard Channick Journal: Clin Appl Thromb Hemost Date: 2019 Jan-Dec Impact factor: 2.389
Authors: Friederike Klein; Sven Möbius-Winkler; Laura Bäz; Rüdiger Pfeifer; Michael Fritzenwanger; Stefan Heymel; Marcus Franz; Pawel Aftanski; P Christian Schulze; Daniel Kretzschmar Journal: Can Respir J Date: 2022-02-27 Impact factor: 2.409
Authors: M De Bucourt; B Gebauer; W M Luedemann; D Zickler; J Kruse; R Koerner; J Lenk; C Erxleben; G F Torsello; U Fehrenbach; M Jonczyk; R W Guenther Journal: Cardiovasc Intervent Radiol Date: 2022-09-29 Impact factor: 2.797